Urokinase receptor and resistance to targeted anticancer agents

Frontiers in Pharmacology

Volumn 6, Issue JUL, 2015, Pages

  Gonias, Steven L ^a   Hu, Jingjing ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer stem cell; Cellular senescence; Epithelial mesenchymal transition; Fibrinolysis; Metastasis; Plasmin; uPAR

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MULTIPROTEIN COMPLEX; PLASMINOGEN; TAMOXIFEN; UROKINASE RECEPTOR;

BREAST CANCER; CANCER CELL LINE; CANCER GROWTH; COLORECTAL CANCER; EGFR GENE; GENE AMPLIFICATION; GENE EXPRESSION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PANCREAS CANCER; PROTEIN TARGETING; REGULATORY MECHANISM; SHORT SURVEY; SMALL CELL LUNG CANCER; UPAR GENE;

EID: 84940040997     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00154     Document Type: Short Survey

References (66)

1. Aguirre Ghiso, J. A., Kovalski, K., and Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104. doi: 10.1083/jcb.147.1.89.
2. Alfano, D., Iaccarino, I., and Stoppelli, M. (2006). Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J. Biol. Chem. 281, 17758-17767. doi: 10.1074/jbc.M601812200.
3. Angst, B. D., Marcozzi, C., and Magee, A. I. (2001). The cadherin superfamily: diversity in form and function. J. Cell Sci. 114, 629-641.
4. Blasi, F., and Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943. doi: 10.1038/nrm977.
5. Boonstra, M. C., Verbeek, F. P., Mazar, A. P., Prevoo, H. A., Kuppen, P. J., Van De Velde, C. J., et al. (2014). Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer 14:269. doi: 10.1186/1471-2407-14-269.
6. Busso, N., Masur, S. K., Lazega, D., Waxman, S., and Ossowski, L. (1994). Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126, 259-270. doi: 10.1083/jcb.126.1.259.
7. Campisi, J., and d'Adda di Fagagna, F. (2007). Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729-740. doi: 10.1038/nrm2233.
8. 5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59, 5307-5314.
9. Cortes-Dericks, L., Carboni, G. L., Schmid, R. A., and Karoubi, G. (2010). Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int. J. Oncol. 37, 437-444.
10. Dano, K., Behrendt, N., Hoyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., et al. (2005). Plasminogen activation and cancer. Thromb. Haemost. 93, 676-681. doi: 10.1160/th05-01-0054.
11. de Paulis, A., Montuori, N., Prevete, N., Fiorentino, I., Rossi, F. W., Visconte, V., et al. (2004). Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and-like 2. J. Immunol. 173, 5739-5748. doi: 10.4049/jimmunol.173.9.5739.
12. Eastman, B. M., Jo, M., Webb, D. L., Takimoto, S., and Gonias, S. L. (2012). A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen. Cell. Signal. 24, 1847-1855. doi: 10.1016/j.cellsig.2012.05.011.
13. Ellis, V. (1996). Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. J. Biol. Chem. 271, 14779-14784.
14. Ellis, V., and Danø, K. (1991). Plasminogen activation by receptor-bound urokinase. Semin. Thromb. Hemost. 17, 194-200. doi: 10.1055/s-2007-1002609.
15. Gewirtz, D. A. (2009). Autophagy, senescence and tumor dormancy in cancer therapy. Autophagy 5, 1232-1234. doi: 10.4161/auto.5.8.9896.
16. Giancotti, F. G., and Ruoslahti, E. (1999). Integrin signaling. Science 285, 1028-1032. doi: 10.1126/science.285.5430.1028.
17. Gilder, A. S., Jones, K. A., Hu, J., Wang, L., Chen, C. C., Carter, B. S., et al. (2015). Soluble uPAR is released selectively by glioblastoma cells that express EGF receptor variant III and promotes tumor cell migration and invasion. J. Biol. Chem. 290, 14798-14809. doi: 10.1074/jbc.M115.637488.
18. Gonias, S. L., Hembrough, T. A., and Sankovic, M. (2001). Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. Front. Biosci. 6, D1403-D1411. doi: 10.2741/gonias.
19. Graham, C. H., Forsdike, J., Fitzgerald, C. J., and Macdonald-Goodfellow, S. (1999). Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer 80, 617-623.
20. Gutova, M., Najbauer, J., Gevorgyan, A., Metz, M. Z., Weng, Y., Shih, C. C., et al. (2007). Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2:e243. doi: 10.1371/journal.pone.0000243.
21. Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., et al. (2005). Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 11, 1462-1466. doi: 10.1158/1078-0432.CCR-04-1737.
22. Hildenbrand, R., Niedergethmann, M., Marx, A., Belharazem, D., Allgayer, H., Schleger, C., et al. (2009). Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am. J. Pathol. 174, 2246-2253. doi: 10.2353/ajpath.2009.080785.
23. Hu, J., Jo, M., Cavenee, W., Furnari, F., Vandenberg, S. R., and Gonias, S. L. (2011). Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 108, 15984-15989. doi: 10.1073/pnas.1113416108.
24. Hu, J., Jo, M., Eastman, B. M., Gilder, A. S., Bui, J. D., and Gonias, S. L. (2014a). uPAR induces expression of transforming growth factor β and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages. Am. J. Pathol. 184, 3384-3393. doi: 10.1016/j.ajpath.2014.08.003.
25. Hu, J., Muller, K. A., Furnari, F. B., Cavenee, W. K., Vandenberg, S. R., and Gonias, S. L. (2014b). Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene doi: 10.1038/onc.2014.336 [Epub ahead of print].
26. Huang, C., Xie, D., Cui, J., Li, Q., Gao, Y., and Xie, K. (2014). FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clin. Cancer Res. 20, 1477-1488. doi: 10.1158/1078-0432.CCR-13-2311.
27. Huang, Z., Wang, L., Wang, Y., Zhuo, Y., Li, H., Chen, J., et al. (2013). Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells. J. Oral Pathol. Med. 42, 541-546. doi: 10.1111/jop.12046.
28. Jo, M., Eastman, B., Webb, D., Stoletov, K., Klemke, R., and Gonias, S. (2010). Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res. 70, 8948-8958. doi: 10.1158/0008-5472.CAN-10-1936.
29. Jo, M., Lester, R., Montel, V., Eastman, B., Takimoto, S., and Gonias, S. (2009a). Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J. Biol. Chem. 284, 22825-22833. doi: 10.1074/jbc.M109.023960.
30. Jo, M., Takimoto, S., Montel, V., and Gonias, S. (2009b). The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am. J. Pathol. 175, 190-200. doi: 10.2353/ajpath.2009.081053.
31. Jo, M., Thomas, K., Marozkina, N., Amin, T., Silva, C., Parsons, S., et al. (2005). Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J. Biol. Chem. 280, 17449-17457. doi: 10.1074/jbc.M413141200.
32. Jo, M., Thomas, K., O'Donnell, D., and Gonias, S. (2003). Epidermal growth factor receptor-dependent and-independent cell-signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278, 1642-1646. doi: 10.1074/jbc.M210877200.
33. Kiyan, J., Kiyan, R., Haller, H., and Dumler, I. (2005). Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-β. EMBO J. 24, 1787-1797. doi: 10.1038/sj.emboj.7600669.
34. Kjoller, L., and Hall, A. (2001). Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152, 1145-1157. doi: 10.1083/jcb.152.6.1145.
35. Koshelnick, Y., Ehart, M., Hufnagl, P., Heinrich, P. C., and Binder, B. R. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272, 28563-28567. doi: 10.1074/jbc.272.45.28563.
36. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., et al. (2003). Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63, 1138-1143.
37. Lester, R., Jo, M., Montel, V., Takimoto, S., and Gonias, S. (2007). uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 178, 425-436. doi: 10.1083/jcb.200701092.
38. Liu, D., Aguirre Ghiso, J., Estrada, Y., and Ossowski, L. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457. doi: 10.1016/S1535-6108(02)00072-7.
39. Lyons, R. M., Keski-Oja, J., and Moses, H. L. (1988). Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J. Cell Biol. 106, 1659-1665. doi: 10.1083/jcb.106.5.1659.
40. Ma, Z., Thomas, K. S., Webb, D. J., Moravec, R., Salicioni, A. M., Mars, W. M., et al. (2002). Regulation of Rac1 activation by the low density lipoprotein receptor-related protein. J. Cell Biol. 159, 1061-1070. doi: 10.1083/jcb.200207070.
41. Ma, Z., Webb, D., Jo, M., and Gonias, S. (2001). Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 114, 3387-3396.
42. Massarweh, S., and Schiff, R. (2006). Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr. Relat. Cancer 13(Suppl. 1), S15-S24. doi: 10.1677/erc.1.01273.
43. 2 integrins in vivo. J. Exp. Med. 188, 1029-1037. doi: 10.1084/jem.188.6.1029.
44. Mazar, A. P. (2008). Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin. Cancer Res. 14, 5649-5655. doi: 10.1158/1078-0432.CCR-07-4863.
45. Meijer-van Gelder, M. E., Look, M. P., Peters, H. A., Schmitt, M., Brunner, N., Harbeck, N., et al. (2004). Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res. 64, 4563-4568. doi: 10.1158/0008-5472.CAN-03-3848.
46. Mignatti, P., and Rifkin, D. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-195.
47. Miles, L. A., and Parmer, R. J. (2013). Plasminogen receptors: the first quarter century. Semin. Thromb. Hemost. 39, 329-337. doi: 10.1055/s-0033-1334483.
48. Mukasa, A., Wykosky, J., Ligon, K. L., Chin, L., Cavenee, W. K., and Furnari, F. (2010). Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc. Natl. Acad. Sci. U.S.A. 107, 2616-2621. doi: 10.1073/pnas.0914356107.
49. Murphy, G., Stanton, H., Cowell, S., Butler, G., Knauper, V., Atkinson, S., et al. (1999). Mechanisms for pro matrix metalloproteinase activation. APMIS 107, 38-44. doi: 10.1111/j.1699-0463.1999.tb01524.x.
50. Nguyen, D., Catling, A., Webb, D., Sankovic, M., Walker, L., Somlyo, A., et al. (1999). Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 146, 149-164. doi: 10.1083/jcb.146.1.149.
51. Nguyen, D., Hussaini, I., and Gonias, S. (1998). Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273, 5802-8507. doi: 10.1074/jbc.273.14.8502.
52. Nguyen, D. H., Webb, D. J., Catling, A. D., Song, Q., Dhakephalkar, A., Weber, M. J., et al. (2000). Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J. Biol. Chem. 275, 19382-19388. doi: 10.1074/jbc.M909575199.
53. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., et al. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 91, 7727-7731. doi: 10.1073/pnas.91.16.7727.
54. Ploug, M., Behrendt, N., Lober, D., and Dano, K. (1991). Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin. Thromb. Hemost. 17, 183-193. doi: 10.1055/s-2007-1002608.
55. Resnati, M., Pallavicini, I., Wang, J., Oppenheim, J., Serhan, C., Romano, M., et al. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. U.S.A. 99, 1359-1364. doi: 10.1073/pnas.022652999.
56. Roldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Dano, K., et al. (1990). Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 9, 467-474.
57. Smith, H. W., and Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11, 23-36. doi: 10.1038/nrm2821.
58. Uhr, J. (2008). uPAR and HER2 genes are usually co-amplified in individual breast cancer cells from blood and tissues. Breast Care (Basel) 3, 16-19. doi: 10.1159/000151738.
59. Voelzke, W. R., Petty, W. J., and Lesser, G. J. (2008). Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr. Treat. Options Oncol. 9, 23-31. doi: 10.1007/s11864-008-0053-5.
60. 1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 168, 501-511. doi: 10.1083/jcb.200404112.
61. 1. Mol. Biol. Cell 12, 2975-2986. doi: 10.1091/mbc.12.10.2975.
62. Wei, Y., Waltz, D., Rao, N., Drummond, R., Rosenberg, S., and Chapman, H. (1994). Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269, 32380-32388.
63. Wykosky, J., Hu, J., Gomez, G. G., Taylor, T., Villa, G. R., Pizzo, D., et al. (2015). A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 75, 394-404. doi: 10.1158/0008-5472.CAN-14-2004.
64. Yamamoto, M., Sawaya, R., Mohanam, S., Rao, V. H., Bruner, J. M., Nicolson, G. L., et al. (1994). Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res. 54, 5016-5020.
65. 5-directed cell migration. J. Biol. Chem. 271, 29393-29399. doi: 10.1074/jbc.271.46.29393.
66. Yu, W., Kim, J., and Ossowski, L. (1997). Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J. Cell Biol. 137, 767-777. doi: 10.1083/jcb.137.3.767.